ArticleClinical and translational radiation oncology2026
Phase II randomized trial of 41.4 Gy vs. 50.4 Gy in neoadjuvant chemoradiotherapy for resectable esophageal cancer.
Ebrahim Esmati et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.